Staufer
Драган Богдановски
- Член од
- 17 јануари 2008
- Мислења
- 16.608
- Поени од реакции
- 22.341
![www.nature.com](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41577-021-00544-9/MediaObjects/41577_2021_544_Fig1_HTML.png)
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination - Nature Reviews Immunology
In this Perspective, Cobey, Larremore, Grad and Lipsitch argue that dose-sparing regimens of COVID-19 vaccines can reduce disease incidence, prevalence and burden and explain why they think that such strategies would also slow the rate of viral escape from vaccine or naturally induced immunity.
![www.nature.com](https://www.nature.com/static/images/favicons/nature/apple-touch-icon.png)
We propose that dose-sparing strategies, which could have large public health benefits, not be dismissed out of concern that they might promote immune escape in SARS-CoV-2. In fact, multiple lines of evidence suggest that expanded vaccination coverage could reduce the rate of immune escape, providing an additional benefit of dose sparing beyond its immediate impact on disease. These beneficial effects hinge on the assumption that vaccination provides some protection against variants of SARS-CoV-2, or, in other words, that vaccine effectiveness against the variants is not zero under dose-sparing regimens. Another requirement is that other fitness-enhancing mutations, such as those allowing for faster replication, do not exclusively occur in genomes with vaccine-escape mutations. Both of these assumptions appear to be met at present. We encourage research to refine our understanding of vaccine effectiveness, immune pressure and the evolutionary dynamics of SARS-CoV-2, and to investigate this problem more thoroughly.